Procaps Group (Procaps Group) Debt-to-Equity : 7.36 (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Procaps Group Debt-to-Equity?

Procaps Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $69.2 Mil. Procaps Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $220.7 Mil. Procaps Group's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $39.4 Mil. Procaps Group's debt to equity for the quarter that ended in Sep. 2023 was 7.36.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Procaps Group's Debt-to-Equity or its related term are showing as below:

PROC' s Debt-to-Equity Range Over the Past 10 Years
Min: -303.86 Med: -1.78 Max: 46.7
Current: 7.36

During the past 4 years, the highest Debt-to-Equity Ratio of Procaps Group was 46.70. The lowest was -303.86. And the median was -1.78.

PROC's Debt-to-Equity is ranked worse than
98.24% of 851 companies
in the Drug Manufacturers industry
Industry Median: 0.29 vs PROC: 7.36

Procaps Group Debt-to-Equity Historical Data

The historical data trend for Procaps Group's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Procaps Group Debt-to-Equity Chart

Procaps Group Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

-1.72

-1.78

-6.77

-303.86

Procaps Group Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Debt-to-Equity	Get a 7-Day Free Trial											-26.52	-303.86	46.70	8.75	7.36

Competitive Comparison of Procaps Group's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Procaps Group's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Procaps Group's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Procaps Group's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Procaps Group's Debt-to-Equity falls into.

Procaps Group Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Procaps Group's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(257.525	+	28.41)	/	-0.941
	=	-303.86

Procaps Group's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(69.238	+	220.682)	/	39.386
	=	7.36

Procaps Group (NAS:PROC) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Procaps Group Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Procaps Group's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Procaps Group (Procaps Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Procaps Group SA (NAS:PROC) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

9X1:Germany

Address

9 Rue de Bitbourg, Luxembourg, LUX, L-1273

Website

https://www.procapsgroup.com

Procaps Group SA is a developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. It develops, manufactures, and markets over-the-counter (OTC) and prescription drugs, nutritional supplements, and high-potency clinical solutions. The company's segment includes NextGel; Procaps Colombia; CAN; CASAND and Diabetrics. It generates maximum revenue from the Procaps Colombia segment.

Executives

Alexandre Weinstein Manieu	director, 10 percent owner	CHASHAM PLACE, FLAT 1, LONDON X0 SW1X 8HG
Ruben Minski	director, 10 percent owner, officer: Chief Executive Officer	9 RUE DE BITBOURG, C/O PROCAPS GROUP, S.A., LUXEMBOURG N4 L-1273
Jose Minski	director, 10 percent owner	9 RUE DE BITBOURG, C/O PROCAPS GROUP, S.A., LUXEMBOURG N4 L-1273
Sognatore Trust	10 percent owner	OFICINA 503A-02, EDIFICIO QUANTUM, (500) RUTA 8 KM. 17.500 ZONAMERICA, MONTEVIDEO X3 91600
Simphony Trust	10 percent owner	29 BANCROFT MILLS ROAD, WILMINGTON DE 19806
Deseja Trust	10 percent owner	29 BANCROFT MILLS ROAD, WILMINGTON DE 19806
Hoche Partners Pharma Holding S.a.	10 percent owner	3A VAL SAINTE CROIX, LUXEMBOURG N4 L-1371